Danaher Corporation has entered strategic partnership with Duke University to form its first Danaher Beacon for Gene Therapy Innovation. Danaher Beacons is a new initiative designed to access breakthrough science to create technologies and applications that will improve human health. The program invests in product innovation to advance external R&D strategies with a focus on genomic medicines, precision diagnostics, next generation biomanufacturing, human systems, and data sciences.

Dr. Aravind Asokan, a synthetic virologist and Duke professor of surgery and biomedical engineering will lead the Danaher Beacon for Gene Therapy Innovation. The focus of this Beacon will be on product solutions that address bottlenecks impacting viral vector manufacturing yield and quality. The partnership began in late October 2022 and is expected to run for multiple years.